乌司奴单抗血药浓度与炎症性肠病临床结局的研究进展  

Progress in understanding of relationship between blood concentrations of ustekinumab and clinical outcomes of inflammatory bowel disease

作　　者：徐文航 范一宏[1] Wen-Hang Xu;Yi-Hong Fan(Department of Gastroenterology,The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310000,Zhejiang Province,China)

机构地区：[1]浙江中医药大学附属第一医院消化内科,浙江省杭州市310060

出　　处：《世界华人消化杂志》2025年第4期261-267,共7页World Chinese Journal of Digestology

基　　金：浙江省中医药科学研究基金项目,No.2021ZA057和No.2022ZB129;浙江省医药卫生科技计划项目,No.2023KY864.

摘　　要：乌司奴单抗由于其疗效及安全性被广泛用于免疫性疾病的治疗,而近年来有研究发现部分患者在长期用药过程中通过调整用药策略,提高药物浓度可明显改善患者预后.治疗药物监测能够反应患者体内乌司奴单抗血药浓度,提供基于药物浓度的治疗策略决定.本综述阐述了乌司奴单抗不同药物浓度与疗效及临床结局关系,并基于现有文献探讨基于治疗药物监测的个体化治疗策略对于临床治疗的价值.Ustekinumab is widely used in the treatment of immune diseases due to its well-established efficacy and safety profile.In recent years,studies have found that adjusting dosing strategies and optimizing drug concentrations during long-term therapy can significantly improve the prognosis of some patients.Therapeutic drug concentration monitoring(TDM)can measure the concentration of ustekinumab in vivo,thereby guiding personalized treatment strategy decisions.This review elaborates on the relationship between different drug concentrations of ustekinumab and clinical efficacy and outcomes,and explores the value of individualized treatment strategies based on TDM for clinical treatment based on the existing literature.

关 键 词：乌司奴单抗 炎症性肠病 治疗药物监测 临床方案 临床结局 

分 类 号：R574[医药卫生—消化系统]